GlassScriptPhysician profile
Chan Ly
NPI 1932736121
$8,103.09
in general payments reported to CMS, 2019-2025
52 companies · $5,190 in 2025
The $5,190 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $960 · 2024: $1,953 · 2025: $5,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,834 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,834.18 |
| Education | $268.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,118.03 | 2023-2025 | Enhertu, Lynparza, Calquence |
| Abbvie INC. | $1,065.73 | 2023-2025 | |
| Janssen Biotech, INC. | $646.92 | 2023-2025 | Rybrevant, Tecvayli, Erleada |
| Regeneron Healthcare Solutions, INC. | $497.29 | 2025 | Libtayo, Lynozyfic |
| Sobi, INC | $415.92 | 2023-2025 | |
| Beone Medicines USA, INC. | $382.95 | 2025 | Tevimbra, Brukinsa |
| Eisai INC. | $279.69 | 2024-2025 | |
| Incyte Corporation | $247.19 | 2024-2025 | Jakafi, Monjuvi, Pemazyre |
| Merck Sharp & Dohme LLC | $244.16 | 2023-2025 | Keytruda, Reblozyl, Welireg |
| Stemline Therapeutics INC. | $237.03 | 2024-2025 | Orserdu |
| Novartis Pharmaceuticals Corporation | $235.03 | 2024-2025 | |
| Gilead Sciences, INC. | $224.90 | 2023-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $156.43 | 2024-2025 | Fruzaqla |
| Janssen Pharmaceuticals, INC | $153.01 | 2023 | Xarelto |
| Daiichi Sankyo INC. | $126.94 | 2024-2025 | Enhertu |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $125.00 | 2023 | |
| Alnylam Pharmaceuticals INC. | $120.62 | 2025 | Givlaari |
| Janssen Scientific Affairs, LLC | $114.30 | 2024 | Erleada |
| Rigel Pharmaceuticals, INC. | $105.16 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Ipsen Biopharmaceuticals, INC | $103.60 | 2024-2025 | Onivyde |
| Tersera Therapeutics LLC | $94.50 | 2025 | Zoladex, Quzyttir |
| Agios Pharmaceuticals, INC. | $93.53 | 2024 | Pyrukynd |
| Tempus Ai, INC | $91.60 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $80.81 | 2025 | Opdivo, Opdualag |
| Pfizer INC. | $80.68 | 2025 | |
| Astellas Pharma US INC | $74.99 | 2025 | |
| Lilly USA, LLC | $66.37 | 2024-2025 | Verzenio, Jaypirca |
| Glaxosmithkline, LLC. | $64.80 | 2024-2025 | Blenrep, Ojjaara, Jemperli |
| Genmab U.S., INC. | $62.84 | 2025 | Epkinly |
| Puma Biotechnology, INC. | $62.09 | 2024-2025 | |
| Array Biopharma INC | $61.73 | 2025 | Xalkori, Braftovi, Lorbrena |
| Celgene Corporation | $58.42 | 2024-2025 | Pomalyst, Reblozyl |
| Progenics Pharmaceuticals, INC. | $53.39 | 2025 | |
| Genentech USA, INC. | $47.51 | 2025 | Polivy, Venclexta |
| Accord Healthcare, INC. | $44.90 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.79 | 2025 | |
| Beigene USA, INC. | $39.41 | 2024-2025 | Brukinsa |
| Legend Biotech USA INC. | $38.76 | 2025 | Carvykti |
| Octapharma USA, INC. | $36.75 | 2025 | Octagam Immune Globulin (Human) |
| Acrotech Biopharma INC. | $35.96 | 2025 | Beleodaq |
| Blueprint Medicines Corporation | $34.88 | 2025 | Ayvakit |
| Syndax Pharmaceuticals, INC. | $32.43 | 2025 | |
| Immunocore Limited | $27.24 | 2025 | Kimmtrak |
| Recordati_rare_diseases_inc. | $26.41 | 2025 | Panhematin |
| Iovance Biotherapeutics, INC. | $25.59 | 2025 | Amtagvi |
| Adc Therapeutics America, INC. | $21.62 | 2025 | |
| Pharmaessentia USA Corporation | $19.43 | 2025 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $18.72 | 2025 | |
| Tolmar, INC. | $17.25 | 2024 | |
| Azurity Pharmaceuticals, INC. | $16.40 | 2024 | Vivimusta |
| Exelixis INC. | $15.87 | 2025 | Cabometyx |
| Genzyme Corporation | $14.52 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chan Ly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.